. 2020 May 21;11(Suppl 2):33–48. doi: 10.1007/s13300-020-00833-x

Table 3.

Absolute risk of severe hypoglycaemia in randomised controlled trials with sulfonylureas

Randomised controlled trials	Duration (years)	Treatments	N	Rate of severe hypoglycaemia
GUIDE 2004 [56]	0.52	Gliclazide MR	405	0
GUIDE 2004 [56]	0.52	Glimepiride	440	0
ADVANCE 2008 [55]	5.0	Gliclazide MR-based intensive control	5571	2.7
ADVANCE 2008 [55]	5.0	Standard control	5569	1.5
Foley et al. 2009 [54]	2.0	Gliclazide	546	0
Foley et al. 2009 [54]	2.0	Vildagliptin	546	0
TOSCA.IT 2017 [42]	4.8	Sulfonylurea^a	1493	1.61
TOSCA.IT 2017 [42]	4.8	Pioglitazone	1535	0.06
CAROLINA 2019 [41]	6.3	Glimepiride	3010	2.2
CAROLINA 2019 [41]	6.3	Linagliptin	3023	0.1

^aGliclazide (n = 745), glimepiride (n = 723) or glibenclamide (n = 24) in accordance with local practice